Nabla Bio is a young biotech startup based in Cambridge, MA that is leveraging the power of artificial intelligence (AI) and machine learning (ML) to co-develop antibodies for difficult-to-treat diseases. Nabla’s Autoverse platform will help them engineer highly targeted antibodies, with their lead antibodies determined through AI-guided optimization. This “end-to-end” platform encompasses the entire antibody creation process, from design to manufacturing, with aims of minimizing manufacturability and toxicity risks. Co-founders include AI and protein experts, Surge Biswas and George Church from Harvard University and Frances Anastassacos.

Nabla Bio

Founded: 2020
Location: Boston, MA
Employee range: 1 - 10
Funding: $11M A Dec 2021

Short description:

Drug notes:

Long description:

Jobs: